Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
Pancreatic cancer
Pancreatic cancer is a rare form of cancer that begins in the pancreas, an essential organ involved in digestion and blood sugar control, but can spread, or metastasize, to other parts of the body. The disease can cause symptoms such as abdominal pain, nausea, fatigue, and jaundice, or a yellowing of the skin and eyes. However, diagnosing pancreatic cancer is difficult because most of its symptoms are unspecific and don’t become evident until the disease has already advanced significantly.
Treatment for pancreatic cancer, a rare cancer that arises from cells in the pancreas, may involve a variety of different approaches, depending on factors such as the stage of disease and a person’s health status. Due to the aggressive nature of the disease, pancreatic cancer survival rates are relatively low. An early diagnosis, when the cancer can still be treated with potentially curative surgery, is critical to improve a person’s pancreatic cancer prognosis. When surgery is not an option, chemotherapy, radiation, and other supportive care measures may help control the cancer and keep patients comfortable for as long as possible.
Latest news
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
